Oligonucleotide Synthesis Market - Global Forecast 2025-2032

The oligonucleotide synthesis market is evolving rapidly, propelled by continued advancements in innovation, automation, and the demand for precision applications spanning research, diagnostics, and therapeutics. Senior decision-makers must navigate shifting sector requirements, complex supply ecosystems, and growing regulatory expectations to exploit emerging growth opportunities.

Market Snapshot: Oligonucleotide Synthesis Market Growth and Trajectory

The global oligonucleotide synthesis market has transitioned from USD 8.81 billion in 2024 to USD 10.28 billion in 2025, maintaining a strong compound annual growth rate (CAGR) of 17.34%. Projections indicate that by 2032, the market is expected to reach USD 31.69 billion. This sustained momentum reflects a robust industry response to rising demand for next-generation therapeutics, increased utilization in custom research applications, and advancing technological capabilities. Industry participants are leveraging innovation-driven approaches to address new use cases in precision medicine and molecular biology.

Scope & Segmentation Across the Oligonucleotide Synthesis Value Chain

• Product Type: Solutions include DNA and RNA synthesizers, microarray synthesizers, labeling and purification reagents, synthesis enzymes, bioinformatics tools, cloud-based storage and management systems, custom oligonucleotide synthesis services, data analysis platforms, as well as both DNA and RNA oligonucleotide products. Sector participants deploy these assets for increased workflow flexibility and data-driven analysis.
• Synthesis Scale: The market covers custom oligonucleotide synthesis projects and large-scale manufacturing for research, diagnostics, and therapeutic development. This flexibility supports agile response to unique project demands and commercial output requirements.
• Delivery Method: The primary synthesis methods utilized are enzymatic synthesis and solid-phase synthesis, each meeting distinct workflow requirements within the laboratory and at industrial scale.
• Application: Utility spans diagnostics (biosensors, molecular imaging, PCR, sequencing), drug discovery and development (target validation, lead optimization), functional genomics, gene expression analysis, gene synthesis, and therapeutic approaches such as antisense therapy, CRISPR-based solution design, and RNA interference. This breadth underscores the platform’s role in modern biomedical research and clinical innovation.
• End-User: The customer base includes academic research institutions, contract research organizations, diagnostics laboratories, and pharmaceutical and biotechnology enterprises, reflecting widespread and diverse adoption.
• Regions: Market adoption is seen across the Americas (including United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (such as United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and the Asia-Pacific region (covering China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan). Regional diversity drives distinct regulatory and innovation landscapes.
• Key Companies: Notable industry participants include Agilent Technologies, Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, Eurofins Genomics, GenScript Corporation, Maravai Intermediate Holdings, PerkinElmer, and Novartis AG, among others.

Key Takeaways for Strategic Decision-Makers

• Recent advancements in chemical and enzymatic oligonucleotide synthesis are accelerating customization and improving quality for both academic and commercial users.
• Workflow digitization, powered by machine learning and automation, is making sequence design, reagent handling, and production more consistent, scaling throughput and efficiency for organizations of all sizes.
• Sustainability considerations—such as adoption of greener chemistries and protocols that cut waste—are influencing market innovation as compliance with environmental regulations intensifies.
• Growing focus on personalized medicine is increasing demand for bespoke oligonucleotides, requiring strategic investment in modular manufacturing and new partnership models to address new therapeutic modalities.
• Integrated end-to-end solutions spanning instrumentation, reagents, informatics, and regulatory integration are emerging as significant factors in sustaining competitive advantage and geographic reach.

Tariff Impact: Navigating United States Tariff Adjustments

The implementation of new tariffs in the United States for 2025 is introducing additional cost pressures throughout the oligonucleotide synthesis value supply chain. Manufacturers are responding to rising costs for inputs such as phosphoramidites and enzymes by diversifying procurement sources, optimizing long-term supplier agreements, and reinforcing regional supply networks. Large organizations are deploying scenario planning tools and predictive analytics to mitigate risks associated with tariff fluctuations and maintain supply chain resilience in an evolving regulatory environment.

Methodology & Data Sources

This analysis leverages a dual-pronged research approach combining rigorous secondary reviews—of peer-reviewed journals, patent filings, industry white papers, and regulatory updates—with targeted primary interviews involving key opinion leaders and senior executives. Data triangulation reinforces the reliability and strategic relevance of all insights presented.

Why This Report Matters: Actionable Insights for Senior Leaders

• Enables data-driven strategic planning with granular market segmentation and opportunity mapping, supporting informed decisions in capital allocation and technology investments.
• Identifies avenues for growth while equipping leaders to anticipate tariff-related and supply chain risks; supports continuity and market positioning in a highly regulated sector.
• Offers validated intelligence to help calibrate product portfolios and guide regulatory compliance initiatives, serving both commercial and scientific goals.

Conclusion

The oligonucleotide synthesis market is responding to fast-paced innovations and global supply chain evolution. Senior leaders who prioritize technology adaptation, sustainability strategies, and partnerships are more likely to secure resilient growth in this shifting landscape.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.